Form 8-K - Current report:
SEC Accession No. 0001157523-22-001777
Filing Date
2022-12-21
Accepted
2022-12-21 07:05:14
Documents
13
Period of Report
2022-12-21
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 ALDEYRA THERAPEUTICS, INC. 8-K a53110252.htm   iXBRL 8-K 33091
2 EXHIBIT 99.1 a53110252ex991.htm EX-99.1 15741
  Complete submission text file 0001157523-22-001777.txt   192715

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA aldx-20221221.xsd EX-101.SCH 3920
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE aldx-20221221_lab.xml EX-101.LAB 22544
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE aldx-20221221_pre.xml EX-101.PRE 16040
7 EXTRACTED XBRL INSTANCE DOCUMENT a53110252_htm.xml XML 4233
Mailing Address 131 HARTWELL AVENUE SUITE 320 LEXINGTON MA 02421
Business Address 131 HARTWELL AVENUE SUITE 320 LEXINGTON MA 02421 781-761-4904
Aldeyra Therapeutics, Inc. (Filer) CIK: 0001341235 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36332 | Film No.: 221476483
SIC: 2834 Pharmaceutical Preparations